IceCure Medical Q2 2026 Earnings Report

IceCure Medical EPS Results

• Actual EPS: -$1.64
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

IceCure Medical Revenue Results

• Actual Revenue: $0.91 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

IceCure Medical Announcement Details

• Quarter: Q2 2026
• Date: 6/30/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

IceCure Medical (NASDAQ:ICCM) (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017. Since then, the company has expanded ProSense’s indications to include treatment of various soft-tissue lesions and small renal tumors. IceCure continues to pursue regulatory approvals in multiple jurisdictions, leveraging partnerships with distributors and clinical research organizations to support both commercial launches and ongoing clinical trials.

With its headquarters located in Caesarea, Israel, IceCure Medical maintains a presence in Europe and Latin America and is actively engaged in preparatory work for entry into the U.S. market. The company has submitted an IDE application with the U.S. Food and Drug Administration to initiate pivotal studies assessing ProSense’s safety and efficacy in the treatment of malignant lesions in the breast. IceCure’s commercial strategy focuses on penetrating high-volume oncology and interventional radiology centers, as well as expanding its footprint through strategic collaborations.

Under the leadership of an experienced management team with deep expertise in interventional oncology and medical device commercialization, IceCure Medical continues to advance its platform through product enhancements and new clinical applications. The company’s ongoing research efforts aim to broaden the utility of its cryoablation technology to address additional indications, underscoring its commitment to offering minimally invasive therapeutic options for cancer and other serious diseases.